https://www.cslseqirus.ca/ 1.0000 2023-09-20 https://www.cslseqirus.ca/fr-fr/ 1.0000 2023-09-20 https://www.cslseqirus.ca/accessibility-statement 0.5000 2022-11-03 https://www.cslseqirus.ca/fr-fr/accessibility-statement 0.5000 2022-11-03 https://www.cslseqirus.ca/globalselector 0.5000 2023-09-20 https://www.cslseqirus.ca/fr-fr/globalselector 0.5000 2023-09-20 https://www.cslseqirus.ca/our-company 0.5000 2023-11-09 https://www.cslseqirus.ca/fr-fr/notre-compagnie 0.5000 2023-11-09 https://www.cslseqirus.ca/r-and-d 0.5000 2023-09-20 https://www.cslseqirus.ca/fr-fr/r-and-d 0.5000 2023-09-20 https://www.cslseqirus.ca/products 0.5000 2025-09-04 https://www.cslseqirus.ca/fr-fr/produits 0.5000 2025-09-04 https://www.cslseqirus.ca/key-customer-information 0.5000 2023-09-20 https://www.cslseqirus.ca/fr-fr/informations-du-client 0.5000 2023-09-20 https://www.cslseqirus.ca/careers 0.5000 2023-09-20 https://www.cslseqirus.ca/fr-fr/carrière 0.5000 2023-09-20 https://www.cslseqirus.ca/news 0.5000 2026-03-06 https://www.cslseqirus.ca/fr-fr/nouvelles 0.5000 2026-03-06 https://www.cslseqirus.ca/contact 0.5000 2025-12-18 https://www.cslseqirus.ca/fr-fr/contact 0.5000 2025-12-18 https://www.cslseqirus.ca/cookie-policy 0.5000 2023-02-02 https://www.cslseqirus.ca/fr-fr/politique-en-matière-de-témoins 0.5000 2023-02-02 https://www.cslseqirus.ca/privacy-statement 0.5000 2024-04-25 https://www.cslseqirus.ca/fr-fr/politique-de-confidentialité 0.5000 2024-04-25 https://www.cslseqirus.ca/terms-of-use 0.5000 2025-05-28 https://www.cslseqirus.ca/fr-fr/conditions-d’utilisation 0.5000 2025-05-28 https://www.cslseqirus.ca/reset-password 0.5000 2019-10-02 https://www.cslseqirus.ca/fr-fr/reset-password 0.5000 2019-10-02 https://www.cslseqirus.ca/search 0.5000 2019-10-02 https://www.cslseqirus.ca/fr-fr/search 0.5000 2019-10-02 https://www.cslseqirus.ca/sitemap 0.5000 2019-10-02 https://www.cslseqirus.ca/fr-fr/plan-du-site 0.5000 2019-10-02 https://www.cslseqirus.ca/our-company/leadership 0.5000 2026-02-10 https://www.cslseqirus.ca/fr-fr/notre-compagnie/direction 0.5000 2026-02-10 https://www.cslseqirus.ca/our-company/leadership/dave-ross 0.5000 2020-05-14 https://www.cslseqirus.ca/fr-fr/notre-compagnie/direction/dave-ross 0.5000 2020-05-14 https://www.cslseqirus.ca/our-company/leadership/chris-larkins 0.5000 2025-05-02 https://www.cslseqirus.ca/fr-fr/notre-compagnie/direction/chris-larkins 0.5000 2025-05-02 https://www.cslseqirus.ca/our-company/leadership/jonathan-edelman 0.5000 2025-05-02 https://www.cslseqirus.ca/fr-fr/notre-compagnie/direction/jonathan-edelman 0.5000 2025-05-02 https://www.cslseqirus.ca/our-company/leadership/lorna-meldrum 0.5000 2025-05-02 https://www.cslseqirus.ca/fr-fr/notre-compagnie/direction/lorna-meldrum 0.5000 2025-05-02 https://www.cslseqirus.ca/our-company/leadership/judi-badenoch 0.5000 2025-05-02 https://www.cslseqirus.ca/fr-fr/notre-compagnie/direction/judi-badenoch 0.5000 2025-05-02 https://www.cslseqirus.ca/our-company/leadership/gregg-sylvester 0.5000 2025-05-02 https://www.cslseqirus.ca/fr-fr/notre-compagnie/direction/gregg-sylvester 0.5000 2025-05-02 https://www.cslseqirus.ca/our-company/leadership/sharon-mchale 0.5000 2025-05-02 https://www.cslseqirus.ca/fr-fr/notre-compagnie/direction/sharon-mchale 0.5000 2025-05-02 https://www.cslseqirus.ca/our-company/leadership/karen-netherton 0.5000 2025-05-02 https://www.cslseqirus.ca/fr-fr/notre-compagnie/direction/karen-netherton 0.5000 2025-05-02 https://www.cslseqirus.ca/our-company/leadership/marcus-de-alwis 0.5000 2025-05-02 https://www.cslseqirus.ca/fr-fr/notre-compagnie/direction/marcus-de-alwis 0.5000 2025-05-02 https://www.cslseqirus.ca/our-company/leadership/chris-thorpe 0.5000 2025-05-07 https://www.cslseqirus.ca/fr-fr/notre-compagnie/direction/chris-thorpe 0.5000 2025-05-07 https://www.cslseqirus.ca/our-company/leadership/stefan-merlo 0.5000 2025-05-07 https://www.cslseqirus.ca/fr-fr/notre-compagnie/direction/stefan-merlo 0.5000 2025-05-07 https://www.cslseqirus.ca/our-company/leadership/paul-davies 0.5000 2025-05-07 https://www.cslseqirus.ca/fr-fr/notre-compagnie/direction/paul-davies 0.5000 2025-05-07 https://www.cslseqirus.ca/our-company/leadership/andrea-scarino 0.5000 2026-02-10 https://www.cslseqirus.ca/fr-fr/notre-compagnie/direction/andrea-scarino 0.5000 2026-02-10 https://www.cslseqirus.ca/our-company/leadership/bertrand-roy 0.5000 2026-02-16 https://www.cslseqirus.ca/fr-fr/notre-compagnie/direction/bertrand-roy 0.5000 2026-02-16 https://www.cslseqirus.ca/our-company/leadership/gill-stafford 0.5000 2025-05-02 https://www.cslseqirus.ca/fr-fr/notre-compagnie/direction/gill-stafford 0.5000 2025-05-02 https://www.cslseqirus.ca/our-company/leadership/ken-lim 0.5000 2025-05-07 https://www.cslseqirus.ca/fr-fr/notre-compagnie/direction/ken-lim 0.5000 2025-05-07 https://www.cslseqirus.ca/our-company/leadership/stephen-marlow 0.5000 2025-05-07 https://www.cslseqirus.ca/fr-fr/notre-compagnie/direction/stephen-marlow 0.5000 2025-05-07 https://www.cslseqirus.ca/news/canada-and-csl-seqirus-agree-on-new-pandemic-preparedness-contract 0.5000 2026-03-06 https://www.cslseqirus.ca/fr-fr/nouvelles/canada-and-csl-seqirus-agree-on-new-pandemic-preparedness-contract 0.5000 2026-03-06 https://www.cslseqirus.ca/news/data-at-idweek-2025 0.5000 2025-11-24 https://www.cslseqirus.ca/fr-fr/nouvelles/data-at-idweek-2025 0.5000 2025-11-24 https://www.cslseqirus.ca/news/essential-protection-for-older-adults 0.5000 2025-11-24 https://www.cslseqirus.ca/fr-fr/nouvelles/essential-protection-for-older-adults 0.5000 2025-11-24 https://www.cslseqirus.ca/news/facility-opens-in-australia 0.5000 2026-01-19 https://www.cslseqirus.ca/fr-fr/nouvelles/facility-opens-in-australia 0.5000 2026-01-19 https://www.cslseqirus.ca/news/news-archives 0.5000 2026-02-12 https://www.cslseqirus.ca/fr-fr/nouvelles/news-archives 0.5000 2026-02-12 https://www.cslseqirus.ca/news/news-archives/seqirus-commends-naci-for-preferential-influenza-for-adults-65-and-older 0.5000 2025-06-16 https://www.cslseqirus.ca/fr-fr/nouvelles/news-archives/seqirus-commends-naci-for-preferential-influenza-for-adults-65-and-older 0.5000 2025-06-16 https://www.cslseqirus.ca/news/news-archives/csl-seqirus-applauds-quebec-govt-decision-to-maintain-universal-influenza-immunization-program 0.5000 2025-06-16 https://www.cslseqirus.ca/fr-fr/nouvelles/news-archives/csl-seqirus-applauds-quebec-govt-decision-to-maintain-universal-influenza-immunization-program 0.5000 2025-06-16 https://www.cslseqirus.ca/news/news-archives/avian 0.5000 2025-12-01 https://www.cslseqirus.ca/fr-fr/nouvelles/news-archives/avian 0.5000 2025-12-01 https://www.cslseqirus.ca/news/news-archives/canadian-audience-only 0.5000 2026-02-12 https://www.cslseqirus.ca/fr-fr/nouvelles/news-archives/canadian-audience-only 0.5000 2026-02-12 https://www.cslseqirus.ca/news/news-archives/canadian-surveys-highlight-flu-ed-with-healthcare-pros-ease-of-access-critical-vaccination-uptake 0.5000 2025-06-16 https://www.cslseqirus.ca/fr-fr/nouvelles/news-archives/canadian-surveys-highlight-flu-ed-with-healthcare-pros-ease-of-access-critical-vaccination-uptake 0.5000 2025-06-16 https://www.cslseqirus.ca/news/news-archives/covid19-update 0.5000 2025-06-16 https://www.cslseqirus.ca/fr-fr/nouvelles/news-archives/covid19-update 0.5000 2025-06-16 https://www.cslseqirus.ca/news/news-archives/csl-seqirus-announces-us-government-award-in-response-to-avian-influenza 0.5000 2025-09-08 https://www.cslseqirus.ca/fr-fr/nouvelles/news-archives/csl-seqirus-announces-us-government-award-in-response-to-avian-influenza 0.5000 2025-09-08 https://www.cslseqirus.ca/news/news-archives/csl-seqirus-ca-gov-of-brit-columbias-decision-make-fluad-publicly-avail-all-brit-columbian-seniors 0.5000 2022-10-28 https://www.cslseqirus.ca/fr-fr/nouvelles/news-archives/csl-seqirus-ca-gov-of-brit-columbias-decision-make-fluad-publicly-avail-all-brit-columbian-seniors 0.5000 2022-10-28 https://www.cslseqirus.ca/news/news-archives/csl-seqirus-proud-to-attend-and-present-at-2023-cic 0.5000 2024-04-24 https://www.cslseqirus.ca/fr-fr/nouvelles/news-archives/csl-seqirus-proud-to-attend-and-present-at-2023-cic 0.5000 2024-04-24 https://www.cslseqirus.ca/news/news-archives/fluad-adjuvanted-flu-vaccines-for-quebec-seniors-csl-seqirus-welcomes-the-ciq-recommendation 0.5000 2025-09-08 https://www.cslseqirus.ca/fr-fr/nouvelles/news-archives/fluad-adjuvanted-flu-vaccines-for-quebec-seniors-csl-seqirus-welcomes-the-ciq-recommendation 0.5000 2025-09-08 https://www.cslseqirus.ca/news/news-archives/health-emergency-readiness-canada 0.5000 2025-10-10 https://www.cslseqirus.ca/fr-fr/nouvelles/news-archives/health-emergency-readiness-canada 0.5000 2025-10-10 https://www.cslseqirus.ca/news/news-archives/idweek-2024 0.5000 2025-12-01 https://www.cslseqirus.ca/fr-fr/nouvelles/news-archives/idweek-2024 0.5000 2025-12-01 https://www.cslseqirus.ca/news/news-archives/nejm-study-cell-based-quadrivalent-influenza-vaccine-efficacy-in-children 0.5000 2024-03-25 https://www.cslseqirus.ca/fr-fr/nouvelles/news-archives/nejm-study-cell-based-quadrivalent-influenza-vaccine-efficacy-in-children 0.5000 2024-03-25 https://www.cslseqirus.ca/news/news-archives/options 0.5000 2025-12-01 https://www.cslseqirus.ca/fr-fr/nouvelles/news-archives/options 0.5000 2025-12-01 https://www.cslseqirus.ca/news/news-archives/seqirus-announces-health-canada-approval-of--first-cell-based-seasonal-influenza-vaccine 0.5000 2020-01-06 https://www.cslseqirus.ca/fr-fr/nouvelles/news-archives/seqirus-announces-health-canada-approval-of--first-cell-based-seasonal-influenza-vaccine 0.5000 2020-01-06 https://www.cslseqirus.ca/news/news-archives/seqirus-announces-health-canada-approval-of-expanded-age-indication 0.5000 2021-03-22 https://www.cslseqirus.ca/fr-fr/nouvelles/news-archives/seqirus-announces-health-canada-approval-of-expanded-age-indication 0.5000 2021-03-22 https://www.cslseqirus.ca/news/news-archives/seqirus-canada-commends-us-acip-preferential-recommendation--enhanced-flu-vaccines-adults-65-and-up 0.5000 2022-07-26 https://www.cslseqirus.ca/fr-fr/nouvelles/news-archives/seqirus-canada-commends-us-acip-preferential-recommendation--enhanced-flu-vaccines-adults-65-and-up 0.5000 2022-07-26 https://www.cslseqirus.ca/news/news-archives/seqirus-presents-key-insights-on-influenza-vaccines 0.5000 2021-03-09 https://www.cslseqirus.ca/fr-fr/nouvelles/news-archives/seqirus-presents-key-insights-on-influenza-vaccines 0.5000 2021-03-09 https://www.cslseqirus.ca/news/news-archives/seqirus-ready-to-reinforce-canadas--influenza-pandemic-preparedness-plans 0.5000 2021-03-23 https://www.cslseqirus.ca/fr-fr/nouvelles/news-archives/seqirus-ready-to-reinforce-canadas--influenza-pandemic-preparedness-plans 0.5000 2021-03-23 https://www.cslseqirus.ca/news/news-archives/seqirus-receives-health-canada-approval-for-expanded-age-indication-for-people-as-young-as-6-months 0.5000 2022-03-28 https://www.cslseqirus.ca/fr-fr/nouvelles/news-archives/seqirus-receives-health-canada-approval-for-expanded-age-indication-for-people-as-young-as-6-months 0.5000 2022-03-28 https://www.cslseqirus.ca/news/news-archives/recently-published-real-world-evidence-study 0.5000 2025-06-16 https://www.cslseqirus.ca/fr-fr/nouvelles/news-archives/recently-published-real-world-evidence-study 0.5000 2025-06-16 https://www.cslseqirus.ca/news/news-archives/seqirus-commends-the-naci-for-preferential-recommendation-of-enhanced-influenza-vaccines-65-plus 0.5000 2025-01-20 https://www.cslseqirus.ca/fr-fr/nouvelles/news-archives/seqirus-commends-the-naci-for-preferential-recommendation-of-enhanced-influenza-vaccines-65-plus 0.5000 2025-01-20 https://www.cslseqirus.ca/contact/report-an-adverse-event 0.5000 2023-09-20 https://www.cslseqirus.ca/fr-fr/contact/signaler-un-événement-indésirable 0.5000 2023-09-20 https://www.cslseqirus.ca/contact/media-contacts 0.5000 2022-11-07 https://www.cslseqirus.ca/fr-fr/contact/contacts-de-médias 0.5000 2022-11-07